Management of Cancer of the Head and Neck - A Cocktail with Your PORT?

New England Journal of Medicine

Volumn 350, Issue 19, 2004, Pages 1997-1999

  Saunders, Michele I ^a,b   Rojas, Ana M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; EDITORIAL; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; NOTE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; CISPLATIN;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; TREATMENT OUTCOME;

EID: 2342533112     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048038     Document Type: Editorial

References (15)

1. Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys 1992;23:737-42.
2. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26:3-11.
3. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55.
4. Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-89.
5. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
6. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy in high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
7. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
8. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
9. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-21.
10. Awwad HK, Lotayef M, Shouman T, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 2002;86:517-23.
11. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8.
12. CHARTWEL, a randomised controlled trial of continuous hyperfractionated accelerated radiotherapy, versus conventional radiotherapy in post-operative head and neck cancer. London: Medical Research Council, 2004. (ISRCTN no. 62576956.)
13. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71. [Erratum, Int J Radiat Oncol Biol Phys 2001;51:569.]
14. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71. [Erratum, Int J Radiat Oncol Biol Phys 2001;51:569.]
15. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 2004;22:19-22.